Volume 7, Issue 1, March 2019, Page: 18-24
Localised Prostate Versus Whole Pelvic Irradiation in High Risk Prostate Cancer, Single Institute Experience
Rasha Mohamed Abdel Latif, Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt
Ghada Ezzat Eladawei, Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt
Received: Jan. 30, 2019;       Accepted: Mar. 12, 2019;       Published: Apr. 1, 2019
DOI: 10.11648/j.crj.20190701.13      View  474      Downloads  39
Objectives: Whole pelvic irradiation [WPRT] versus prostate only radiation [PO-RT] in node negative high risk disease is controversial. This study aims to assess survival benefit of PO-RT against WPRT in high risk negative nodes prostate cancer. Patients and Methods: Patients with high risk prostate cancer and negative pelvic lymph nodes treated randomly either with WPRT [arm1] or PORT [arm2] from June-2014-June-2017. Eligible patients were ˃18 years, risk factors selected are ≥T3, GS≥8, or PSA≥20nglml. All patients received hormonal therapy as neo-adjuvant and concurrent with radiation and followed to 2-3 years. Univariate and multivariate analysis are performed. The primary end point was progression free survival [PFS], and the secondary was OAS and toxicity assessment. Results: Ninety four patients included, 48 received WPRT arm and 46 received PORT. With median follow up 26 months there was no significant difference in PFS, or OAS [P=0.994 and 0.505] respectively between both arms. On univariate analysis PFS was significantly better in lower stage [P=0.014], lower GS [P=0.000], lower number of risk factors [P=0.016]. Only 2 cases with late grade 3 gastrointestinal toxicity in observed in WPRT [P=0.044], and one case late grade 3 genitourinary in PORT with no significance [P=0.096]. Conclusion: Addition of pelvic irradiation in high risk node negative prostate cancer has no impact on survival in comparison to PORT.
Prostate Cancer, Nodal Irradiation, Pelvic Radiation, High Risk
To cite this article
Rasha Mohamed Abdel Latif, Ghada Ezzat Eladawei, Localised Prostate Versus Whole Pelvic Irradiation in High Risk Prostate Cancer, Single Institute Experience, Cancer Research Journal. Vol. 7, No. 1, 2019, pp. 18-24. doi: 10.11648/j.crj.20190701.13
Copyright © 2019 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Amal S., Hussein M., Nabiel N., Hoda Baraka, and Hossam Kamel: Cancer incidence in Egypt: Results of the National population based cancer registery program. J Cancer Epidemiol. 2014 :437971.
Arfa M., Rabah D., Wahdan I. : Awareness of general public towards cancer prostate & screening practice in Arabic communities: a comparative multi-center study. Asian Pac. J. Cancer Prev. 2012; 13:4321-4326.
American Cancer Society, Prostate Cancer, 2015.
Cooperberg M., Broering J., & Carroll P.,: Time trends and local variation in primary treatment of localized prostate cancer. J. Clin. Oncol. 2010; 28:1117–1123 .
Thompson I., Thrasher J., Aus G., Burnett A., Canby-Hagino E., Cookson M., et al.: Guideline for the management of clinically localized prostate cancer: J. Urol. 2007; 177: 2106–2131.
Roach III M., Lu J., Pilepich M., Asbell S., Mohiuddin M., Terry R., et al: Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials. Int. J. Radiat. Oncol. Biol. Phys. 2000; 47: 609–615 .
Roach III M., Weinberg V., Nash M., Sandler H., McLaughlin P., Kattan M.: Defining high risk prostate cancer with risk groups and nomograms: implications for designing clinical trials. J. Urol.2006; 176:16–20.
Coen J., Zietman A., Thakral H., Shipley W.: Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases. Journal of Clinical Oncology, 2002; 20: 3199–3205.
Zelefsky M., Reuter V., Fuks Z., Scardino P, Shippy A.: Influence of local tumor control on distant metastases and cancer related mortality after external beam radiotherapy for prostate cancer. Journal of Urology, 2008; 179:1368–1373.
Pilepich M., Winter K., Lawton C., Krisch R., Wolkov H., Movsas B., et al: Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31. Int. J. Radiat. Oncol. Biol. Phys. 2005; 61:1285–1290 .
Widmark A., Klepp O., Solberg A., Damber J, Angelsen A, Fransson P, et al.: Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer [SPCG-7/SFUO-3]: an open randomised phase III trial. The Lancet. 2009; 373: 301–308.
Warde P., Mason M., Ding K., Kirkbride P., Brundage M., Cowan R., et al: Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. The Lancet.2011; 378: 2104–2111.
Mason M., Parulekar W., Sydes M., Brundage M., Kirkbride P., Gospodarowicz M., et al.: Final report of the intergroup randomized study of combined androgen-deprivation therapy plus radiotherapy versus androgen-deprivation therapy alone in locally advanced prostate cancer. Journal of Clinical Oncology. 2015; 33: 2143–2150.
Roach III M., Marquez C., You H., Narayan P., Coleman L., Nseyo U., et al.: Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys.1994; 28:33–37.
Roach III M., DeSilvio M., Valicenti R., Grignon D., Asbell S., Lawton C., et al.: Whole-pelvis, “mini-pelvis,” or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial. Int. J. Radiat. Oncol. Biol. Phys. 2006; 66: 647–653.
Roach M III., DeSilvio M., Lawton C., Uhl V., Machtay M., Seider M., et al: Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol.2003; 21:1904-1911.
Roach III M., Hunt D., Lawton C., Hsu I., Lustig R., Seider M., et al.: R adiation Therapy Oncology Group [RTOG] 9413: a randomized trial comparing Whole Pelvic Radiation Therapy [WPRT] to Prostate only [PORT] and Neoadjuvant Hormonal Therapy [NHT] to Adjuvant Hormonal Therapy [AHT]. Int. J. Radiat. Oncol. Biol. Phys. 2013 ; 87:106–107.
Aizer A., Yu J., McKeon A., Decker R., Colberg J., Peschel R.: Whole pelvic radiotherapy versus prostate only radiotherapy in the management of locally advanced or aggressive prostate adenocarcinoma. Int J Radiat Oncol Biol Phys. 2009; 75:1344-1349.
Cozzarini C., Noris Chiorda B., Sini C., Fiorino C., Briganti A., Montorsi F., et al. Hematologic toxicity in patients treated with post-prostatectomy whole-pelvis irradiation with different intensity modulated radiation therapy techniques is not negligible and is prolonged: Preliminary results of a longitudinal, observational study. Int J Radiat Oncol Biol Phys. 2016; 95: 690–695.
Ennis R.: Uncertainties regarding pelvic radiotherapy for prostate cancer. J Clin Oncol .2004; 22:2254-2255.
Vargas C., Galalae R., Demanes J., Harsolia A., Meldolesi E., Nürnberg N., et al: Lack of benefit of pelvic radiation in prostate cancer patients with a high risk of positive pelvic lymph nodes treated with high-dose radiation. Int J Radiat Oncol Biol Phys.2005; 63:1474-1482.
Pommiere P., Chabaud S., Leon J., Richaud P., Lesaunier F., Le Prise E., et al.: Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. J Clin Oncol. 2007; 25:5366-5373.
Lawton C., DeSilvio M., Roach III M., Uhl V, Kirsch R, Seider M., et al.: An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int. J. Radiat. Oncol. Biol. Phys. 2007; 69: 646–655.
Amini A., Jones B., Yeh N., Rusthoven C., Armstrong H., Kavanagh B.: Survival Outcomes of Whole-Pelvic Versus Prostate-Only Radiation Therapy for High-Risk Prostate Cancer Patients With Use of the National Cancer Data Base. Int J Radiat Oncol Biol Phys.2015; 93: 1052-1063.
Mohler J., Kantoff P., Armstrong A., Bahnson R., Cohen M., D'Amico A., et al.: Prostate cancer, version 2.2014,” Journal of the National Comprehensive Cancer Network.2015; 12: 686–718.
Albert J., Karen A., Roach III M., Howard I. . High-risk prostate cancer—classification and therapy. Nature Reviews Clinical Oncology. 2015; 11:308-323.
Kuban D, Tucker S, Dong L, et al. Long-term results of the MD Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008; 70:67-74.
Zietman A., DeSilvio M., Slater J., Rossi C., Miller D., Adams J., et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial. JAMA. 2005; 294:1233-1239.
Michalski J, Moughan J, Purdy J, Bosch W., Bahary J., Lau H., et al. A randomized trial of 79.2 Gy versus 70.2 Gy radiation therapy [RT] for localized prostate cancer. J Clin Oncol. 2015; 33 [suppl 7; abstr 4].
Valicenti RK, Bae K, Michalski J, Sandler, H., Shipley, W., Lin, A., et al. Does hormone therapy reduce disease recurrence in prostate cancer patients receiving dose-escalated radiation therapy? An analysis of Radiation Therapy Oncology Group 94-06. Int J Radiat Oncol Biol Phys. 2011; 79: 1323 -1329.
Pan C., Kim K., Taylor J., McLaughlin P., Sandler H.: Influence of 3D-CRT pelvic irradiation on outcome in prostate cancer treated with external beam radiotherapy. Int J Radiat Oncol Biol Phys.2002; 53:1139-1145.
Asbell S, Krall J, Pilepich M, Baerwald H., Sause W., Hank G., et al: Elective pelvic irradiation in stage A2, B carcinoma of the prostate: Analysis of RTOG 77-06. Int J Radiat Oncol Biol Phys.1988; 15:1307-1316.
Asbell S, Martz K, Shin K, Sause W., Doggett R., Perez C., et al: Impact of surgical staging in evaluating the radiotherapeutic outcome in RTOG #77-06, a phase III study for T1BN0M0 [A2] and T2N0M0 [B] prostate carcinoma. Int J Radiat Oncol Biol Phys. 1998; 40:769-782.
Lawton CA, DeSilvio M, Roach M, Uhl V, Kirsch R, Seider M., et al: An update of the phase III trial comparing whole-pelvic [WP] to prostate only [PO] radiotherapy and neoadjuvant to adjuvant total androgen suppression [TAS]: Updated analysis of RTOG 94-13. Int J Radiat Oncol Biol Phys.2005; 63:S19 [suppl].
Seaward S., Weinberg V., Lewis P., Leigh B. , Phillips T., Roach III M.. Identification of a high-risk clinically localized prostate cancer subgroup receiving maximum benefit from whole-pelvic irradiation. Cancer J Sci Am. 1998; 4:370-377.
Milecki P., Baczyk M., Skowronek J., Andrzej , Zbigniew K, Piotr l. Benefit of whole pelvic radiotherapy combined with neoadjuvant androgen deprivation for the high-risk prostate cancer. J Biomed Biotechnol 2009; 625394.
Lior Z, Mig-Hui C, Daniel , Sharon A., Michael J., Akash N., et al. Whole pelvis versus prostate-only radiotherapy with or without short course androgen deprivation therapy and mortality risk. Cl Genitour cancer. 2015; 13: 555–561.
Vargas C, Demanes J, Boike T, Barnaba M., Skoolisariyaporn P., Schour L., et al. Matched-pair analysis of prostate cancer patients with a high risk of positive pelvic lymph nodes treated with and without pelvic RT and high-dose radiation using high dose rate brachytherapy. Am J Clin Oncol. 2006; 29:451-457.
Soto D, Glaser S, Roberts R, Schipper M., McLaughlin P., Ray M., et al. Impact of common iliac nodal treatment on radiation outcomes in localized prostate cancer. Urology 2008; 71:313-317.
Jacob R., Hanlon A., Horwitz E., Movsas B., Uzzo R., Pollack A. Role of prostate dose escalation in patients with greater than 15% risk of pelvic lymph node involvement. Int J Radiat Oncol Biol Phys. 2005; 61: 695-701.
Perez C, Michalski J, Brown K, Ann L.: Nonrandomized evaluation of pelvic lymph node irradiation in localized carcinoma of the prostate. Int J Radiat Oncol Biol Phys.1996; 36:573-584.
Browse journals by subject